European Union announces new programme to improve Parkinson’s diagnosis

News

Author: Parkinson's Life editorsPublished: 17 January 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

PD-Podcast-DBS

The European Union has announced the launch of the Magnetic Diagnostic Assay for Neurodegenerative Diseases (MADIA) – a project with the ultimate goal of improving diagnosis for those living with Parkinson’s and Alzheimer’s.

The project, which is in partnership with a range of international universities and institutions, will focus on the development of a novel device that will help clinicians perform a simple click and analysis to diagnose both conditions.

Dr Francisco Campos, of the Clinical Neurosciences Research Laboratory, said: “An early diagnosis is crucial to maximise the effectiveness of the treatments in order to mitigate the devastating effects of these illnesses and slow disease progression.

“MADIA is funded by the European Union’s Horizon 2020 research and innovation programme, and consists of a multitasking team with more than 50 professionals in the fields of biology, physics and engineering.”

For comprehensive information about Parkinson’s diagnosis please visit Parkinson’s Europe website.

Go Back

Share this story

Comments


Related articles


Women and Parkinson's

Women and Parkinson’s: “Being pregnant was scary”

One woman’s poignant account of pregnancy and Parkinson’s

READ MORE
Carer's Week lead image

Carers' Corner

10 shocking facts that show what it’s like to be a carer

Highlighting the issues faced by carers throughout Europe

READ MORE
Duodopa approved in Scotland lead

Advances

Parkinson’s campaigners win fight to have life-changing drug approved

Drug that can “transform” lives is approved for use in Scotland

READ MORE